Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha 2b: Implications for cancer vaccines

Astsaturov, I; Petrella, T; Bagriacik, EMİN; de Benedette, M; Uger, R; Lumber, G; Berinstein, N; Elias, I; Iscoe, N; Hammond, C; Hamilton, P; Spaner, DE

Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha 2b: Implications for cancer vaccines

Atıf İçin Kopyala

Astsaturov I., Petrella T., Bagriacik E. Ü., de Benedette M., Uger R., Lumber G., ...Daha Fazla

CLINICAL CANCER RESEARCH, cilt.9, sa.12, ss.4347-4355, 2003 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 9 Sayı: 12
Basım Tarihi: 2003
Dergi Adı: CLINICAL CANCER RESEARCH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.4347-4355
Gazi Üniversitesi Adresli: Evet

Özet

Purpose: The therapeutic effectiveness of cancer vaccines, composed of tumor antigens that are also self-antigens, may be limited by the normal mechanisms that preserve immunological tolerance. Consistent with this notion, we found that vaccination of melanoma patients with recombinant viral vaccines expressing gp100 (a melanoma antigen also expressed by normal melanocytes) produced only transient increases in noncytotoxic T cells specific for immunodominant gp100 epitopes. To improve the therapeutic effects of these vaccines, IFN-alpha2b (IFN-alpha) was administered to some high-risk patients.